Welcome to our dedicated page for Primerica SEC filings (Ticker: PRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Primerica鈥檚 life-insurance reserves, commission payouts, and the size of its licensed-representative force can be daunting; the company鈥檚 annual report alone spans hundreds of pages packed with actuarial tables and deferred acquisition cost roll-forwards. If you have ever searched for 鈥淧rimerica SEC filings explained simply鈥� or tried to pinpoint the latest 鈥淧rimerica quarterly earnings report 10-Q filing,鈥� you know how quickly EDGAR becomes overwhelming. Digging through 鈥淧rimerica insider trading Form 4 transactions鈥� for clues about executive sentiment only adds to the complexity.
Stock Titan resolves this with AI-powered summaries that translate insurance jargon into clear language, turning 鈥渦nderstanding Primerica SEC documents with AI鈥� from aspiration into reality. Our engine highlights solvency ratios, segment revenue, and policy lapse trends and instantly flags 鈥淧rimerica Form 4 insider transactions real-time,鈥� so you never miss a key share purchase or sale. Even the 鈥淧rimerica annual report 10-K simplified鈥� arrives within moments of EDGAR release, annotated with plain-English explanations of reserve adjustments and capital requirements.
Use our platform to:
- Receive concise 鈥淧rimerica earnings report filing analysis鈥� minutes after each release.
- Monitor 鈥淧rimerica executive stock transactions Form 4鈥� alongside our risk-weighted scoring.
- Dive into 鈥淧rimerica proxy statement executive compensation鈥� tables without scanning 100+ pages.
- Get 鈥淧rimerica 8-K material events explained鈥� so you understand how reinsurance treaties or distributor agreements affect valuation.
Every filing type鈥�10-K, 10-Q, 8-K, DEF 14A, S-8鈥攊s updated in real time and paired with expert commentary. Make informed decisions faster by converting dense disclosures into actionable insights.
Insider sale by Primerica President Peter W. Schneider. The Form 4 shows Mr. Schneider executed a sale of 2,000 shares of Primerica, Inc. (PRI) on 08/18/2025 at an average price of $261.1649, with reported trade prices ranging from $259.64 to $262.48. After the sale he beneficially owned 9,301 shares, reported as direct ownership.
The filing indicates the transaction was made pursuant to a 10b5-1 trading plan (box checked). The Form 4 was signed by an attorney-in-fact, Stacey K. Geer, on 08/19/2025. No derivative transactions or other securities classes are reported.
Form 144 filed for Primerica, Inc. (PRI) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $1,046,680.00. The shares were originally acquired as restricted stock awards on 02/21/2015. The filer previously sold 2,000 shares on 05/19/2025 under a 10b5-1 plan, generating gross proceeds of $560,739.40. The filing lists 32,391,333 shares outstanding for the issuer and states the sale will occur on the NYSE.
Primerica reported a Form 4 showing that Glenn J. Williams, who is listed as both a director and the Chief Executive Officer, disposed of shares on 08/12/2025. The filing records a sale of 2,500 shares of Common Stock at a weighted average price of $262.2035. After the reported sale, Mr. Williams is shown as beneficially owning 36,391.995 shares directly. The transaction is coded as a sale and the form was executed on 08/12/2025 by Stacey K. Geer as attorney in fact. The filer explains the weighted average reflects multiple trade prices ranging from $259.22 to $264.34.
Primerica, Inc. (PRI) filed a Form 144 notifying a proposed sale of 2,500 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an indicated aggregate market value of $645,675.00. The shares were acquired as Restricted Stock Units on 03/01/2025 and the filing lists an approximate sale date of 08/12/2025. The filing also discloses a prior 10b5-1 sale of 2,500 shares on 06/13/2025 generating gross proceeds of $647,591.25. Outstanding shares are shown as 32,391,333, making the proposed block a very small percentage of the company.
Primerica Q2 2025 10-Q highlights
- Revenue inched up 0.3% YoY to $793.3 million; commissions & fees rose 14% while net premiums grew 3.6%.
- Pre-tax income from continuing ops fell 14% to $234.5 million; net income declined to $178.3 million (-15%) as prior-year results contained a one-off $50 million insurance recovery.
- Diluted EPS from continuing ops dropped to $5.40 (-11%); total diluted EPS unchanged by discontinued Senior Health unit, which caused a $208 million loss in Q2 2024.
- Segment performance: Term Life pre-tax profit +5% to $155.0 million; Investment & Savings Products +6% to $79.4 million; Corporate & Other near breakeven versus $50.2 million profit last year.
- Capital returns: 2Q buybacks of $127 million and dividends of $34 million reduced diluted share count 4% YoY to 32.9 million; YTD repurchases total $251 million.
- Balance sheet: Assets $14.83 b (+2% YTD); equity $2.31 b (+2%). Cash fell to $621 million after $329 million financing outflows. AOCI improved by $63 million YTD on discount-rate and FX movements.
- Liquidity & cash flow: Operating cash flow solid at $360 million versus $384 million YTD 2024; investing cash outflow $100 million driven by portfolio reinvestment.
Bottom line: Core franchises showed modest growth, but elevated expenses and loss of 2024鈥檚 non-recurring gain compressed margins. Shareholder payouts remain aggressive, sustaining mid-teens ROE.
FAQ
What is the current stock price of Primerica (PRI)?
What is the market cap of Primerica (PRI)?
